Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 242

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

A therapeutic aptamer inhibits angiogenesis by specifically targeting the heparin binding domain of VEGF 165

Open access
Lee, Joon-Hwa, Canny, Marella D., De Erkenez, Andrea, Krilleke, Dominik, Ng, Yin-Shan, Shima, David T., Pardi, Arthur, Jucker, Fiona·2005·Proceedings of the National Academy of Sciences

Abstract

Aptamers recognize their targets with extraordinary affinity and specificity. The aptamer-based therapeutic, Macugen, is derived from a modified 2′fluoro pyrimidine RNA inhibitor to vascular endothelial growth factor (VEGF) and is now being used to treat the wet form of age-related macular degeneration. This VEGF 165 aptamer binds specifically to the VEGF 165 isoform, a dimeric protein with a receptor-binding domain and a heparin-binding domain (HBD). To understand the molecular recognition between VEGF and this aptamer, binding experiments were used to show that the HBD contributes the majority of binding energy in the VEGF 165 –aptamer complex. A tissue culture-based competition assay demonstrated that the HBD effectively competes with VEGF 165 for aptamer binding in vivo . Comparison of NMR spectra revealed that structural features of the smaller HBD–aptamer complex are present in the full-length VEGF 164 –aptamer complex. These data show that the HBD provides the binding site for the aptamer and is the primary determinant for the affinity and specificity in the VEGF 165 –aptamer complex.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.0509069102

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 242

Metadata

Authors
Lee, J.-H., Canny, M. D., De Erkenez, A., Krilleke, D., Ng, Y.-S., Shima, D. T., Pardi, A., & Jucker, F.
Venue
Proceedings of the National Academy of Sciences
Published
2005-12-15
Volume
102
Issue
52
Pages
18902-18907
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W2118548020
Cited by
242
References
2
FWCI
4.96
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A therapeutic aptamer inhibits angiogenesis by specifically targeting the heparin binding domain of VEGF 165. https://app.cochat.ai/papers/10.1073/pnas.0509069102
The paper
Lee, J.-H., Canny, M. D., De Erkenez, A., Krilleke, D., Ng, Y.-S., Shima, D. T., Pardi, A., & Jucker, F. (2005). A therapeutic aptamer inhibits angiogenesis by specifically targeting the heparin binding domain of VEGF 165. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.0509069102

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.